Upstream effect for atrial fibrillation: still a dilemma?

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a prevalent clinical arrhythmia.
• Current treatments, including ion channel blockers and ablative procedures, have limitations in efficacy, safety, and accessibility.
• Atrial remodeling is a key factor in AF development and maintenance.

Purpose of the Study:

• To review the mechanisms and clinical evidence of "upstream therapy" in managing atrial fibrillation.
• To explore how upstream therapies influence atrial structural and electrical remodeling.
• To discuss the potential of upstream therapy as a substrate-targeting strategy for AF.

Main Methods:

• Literature review of "upstream therapy" agents and their impact on atrial fibrillation.
• Analysis of mechanisms underlying atrial remodeling influenced by these agents.
• Synthesis of clinical evidence supporting the efficacy of upstream therapy.

Main Results:

• Upstream therapies, including ACE inhibitors, aldosterone antagonists, statins, glucocorticoids, and ω-3 fatty acids, target the substrate of AF.
• These therapies modulate atrial structural and electrical remodeling, crucial for AF induction and maintenance.
• Clinical evidence suggests potential long-term benefits and improved safety profiles compared to conventional treatments.

Conclusions:

• Upstream therapy represents a significant shift towards targeting the underlying substrate of atrial fibrillation.
• This approach holds promise for improving long-term management of AF by addressing remodeling processes.
• Further research is needed to address open questions and optimize the clinical application of upstream therapies.